Achieving Canadian Treat-to-Target Criteria in Moderate-to-Severe Atopic Dermatitis: A Retrospective Analysis of Outcomes from Real-World Canadian Practice - Report - MDSpire
Advertisement
Achieving Canadian Treat-to-Target Criteria in Moderate-to-Severe Atopic Dermatitis: A Retrospective Analysis of Outcomes from Real-World Canadian Practice
Clinical Report: Meeting Canadian Treat-to-Target Standards in Atopic Dermatitis
Overview
This retrospective study evaluated the applicability of Canadian treat-to-target (T2T) recommendations for moderate-to-severe atopic dermatitis (AD) by analyzing treatment outcomes of 297 patients.
Background
Treat-to-target (T2T) strategies aim to enhance disease management in chronic conditions, including moderate-to-severe atopic dermatitis, by establishing measurable treatment goals. The validation of these targets in real-world settings is crucial for guiding treatment modifications. This study represents an initial effort to assess the effectiveness of T2T criteria proposed by Canadian dermatologists in clinical practice.
Data Highlights
No numerical data or trial data were provided in the source material.
Key Findings
Retrospective evaluation involved 297 patients treated with advanced systemic therapies for moderate-to-severe AD.
Target criteria were applied to assess treatment outcomes over a period of up to 12 months.
Decisions to continue or modify treatment were generally aligned with whether patients met or missed the established targets.
This evaluation is a preliminary step toward validating the Canadian T2T recommendations for AD.
Clinical Implications
The alignment of treatment decisions with target achievement suggests that T2T criteria may assist clinicians in making treatment modifications.
Conclusion
The study provides initial evidence supporting the real-world applicability of Canadian T2T recommendations for atopic dermatitis.
